1 asset in Fibrous Dysplasia

Therapeutic assets addressing Fibrous Dysplasia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Burosumab Fibrous Dysplasia	National Institute of Dental and Craniofacial Research (NIDCR)	P2	B (57)